MetabolicIn Clinical Trials

Cagrilintide

Subcutaneous injection

Overview

Cagrilintide is a long-acting amylin analogue engineered with structural modifications to extend half-life and enable once-weekly dosing for the treatment of obesity and type 2 diabetes. Amylin is a 37-amino-acid neuroendocrine hormone co-secreted with insulin that reduces food intake by slowing gastric emptying, enhancing satiety, and modulating central appetite pathways.

Mechanism of Action

Cagrilintide selectively activates amylin receptors in the area postrema and other key brain regions involved in energy homeostasis..

Research Summary & Key Findings

Phase 2 trials published in Lancet (2021) demonstrated dose-dependent weight loss as monotherapy and synergistic effects when combined with GLP-1 receptor agonists such as semaglutide. The combination regimen (CagriSema) is advancing through phase 3 development with interim data presented in 2023 showing weight reductions approaching 15 to 20 percent, positioning it among the most effective pharmacologic obesity interventions under investigation.

Clinical Status

In Clinical Trials

Cagrilintide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Find a Provider

Find a verified provider who offers Cagrilintide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cagrilintide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.